FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655505> ?p ?o ?g. }

• W4385655505 endingPage "2620" @default.
• W4385655505 startingPage "2620" @default.
• W4385655505 abstract "Prognosis in recurrent/metastatic head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is poor, making therapy optimization a priority. Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody Nivolumab was approved in such cases. We present the early experience with Nivolumab immunotherapy at three cancer clinics from south and northeast Romania, aiming to describe the main characteristics and outcomes relative to literature reports, and to suggest patient selection criteria. Diagnostic, clinical, biological, therapeutic, and outcomes-related data from January 2020 until March 2023 were analyzed retrospectively. Eighteen patients with platinum refractory HNSCC (85.7% men, median age 58.9) were administered Nivolumab for 1–14 months (median 5.6 months) in addition to other treatments (surgery, radiotherapy, chemotherapy), and monitored for up to 25 months. Median neutrophil-to-lymphocyte ratio (NLR) ranged from 2.72 initially to 6.01 during treatment. Overall survival (OS) was 16 months, and patients who died early had the sharpest NLR increases (13.07/month). There were no severe immune-related adverse events. Lower NLR values and combined intensive chemotherapy, radiotherapy, and immunotherapy were related to better outcomes. To our knowledge, we also report the first two cases of second primary malignancy (SPM) in the head and neck region treated with Nivolumab in Romania (for which the sequential administration of radiotherapy and immunotherapy seems better). The work of other Romanian authors on the role of HPV status in HNC is also discussed. Multi-center trials are needed in order to investigate and confirm these observations." @default.
• W4385655505 created "2023-08-09" @default.
• W4385655505 creator A5016162569 @default.
• W4385655505 creator A5016725149 @default.
• W4385655505 creator A5029343418 @default.
• W4385655505 creator A5058079493 @default.
• W4385655505 creator A5067920206 @default.
• W4385655505 creator A5069294276 @default.
• W4385655505 creator A5075491391 @default.
• W4385655505 creator A5086673665 @default.
• W4385655505 date "2023-08-08" @default.
• W4385655505 modified "2023-10-18" @default.
• W4385655505 title "Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review" @default.
• W4385655505 cites W2089257078 @default.
• W4385655505 cites W2397540382 @default.
• W4385655505 cites W2529484692 @default.
• W4385655505 cites W2537963082 @default.
• W4385655505 cites W2557078803 @default.
• W4385655505 cites W2603127500 @default.
• W4385655505 cites W2605497049 @default.
• W4385655505 cites W2732565107 @default.
• W4385655505 cites W2735818385 @default.
• W4385655505 cites W2783295481 @default.
• W4385655505 cites W2811294642 @default.
• W4385655505 cites W2903493423 @default.
• W4385655505 cites W2922097565 @default.
• W4385655505 cites W2947220160 @default.
• W4385655505 cites W2955839328 @default.
• W4385655505 cites W2966695676 @default.
• W4385655505 cites W2975274775 @default.
• W4385655505 cites W2978527819 @default.
• W4385655505 cites W2994683483 @default.
• W4385655505 cites W2994821603 @default.
• W4385655505 cites W2998700378 @default.
• W4385655505 cites W3002787057 @default.
• W4385655505 cites W3004487982 @default.
• W4385655505 cites W3014595586 @default.
• W4385655505 cites W3016514471 @default.
• W4385655505 cites W3026899880 @default.
• W4385655505 cites W3033152242 @default.
• W4385655505 cites W3033909630 @default.
• W4385655505 cites W3042992468 @default.
• W4385655505 cites W3080889076 @default.
• W4385655505 cites W3087486990 @default.
• W4385655505 cites W3104254817 @default.
• W4385655505 cites W3112112309 @default.
• W4385655505 cites W3118050775 @default.
• W4385655505 cites W3127371144 @default.
• W4385655505 cites W3128365914 @default.
• W4385655505 cites W3128740687 @default.
• W4385655505 cites W3134959030 @default.
• W4385655505 cites W3138819603 @default.
• W4385655505 cites W3147500389 @default.
• W4385655505 cites W3180153055 @default.
• W4385655505 cites W3180193880 @default.
• W4385655505 cites W3189212793 @default.
• W4385655505 cites W3195801219 @default.
• W4385655505 cites W3207983141 @default.
• W4385655505 cites W4200063562 @default.
• W4385655505 cites W4200154065 @default.
• W4385655505 cites W4200272568 @default.
• W4385655505 cites W4206838101 @default.
• W4385655505 cites W4210563021 @default.
• W4385655505 cites W4210876582 @default.
• W4385655505 cites W4213296860 @default.
• W4385655505 cites W4223983158 @default.
• W4385655505 cites W4226140573 @default.
• W4385655505 cites W4281659326 @default.
• W4385655505 cites W4281786676 @default.
• W4385655505 cites W4285039629 @default.
• W4385655505 cites W4285719527 @default.
• W4385655505 cites W4300863791 @default.
• W4385655505 cites W4303628882 @default.
• W4385655505 cites W4306921237 @default.
• W4385655505 doi "https://doi.org/10.3390/diagnostics13162620" @default.
• W4385655505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37627878" @default.
• W4385655505 hasPublicationYear "2023" @default.
• W4385655505 type Work @default.
• W4385655505 citedByCount "0" @default.
• W4385655505 crossrefType "journal-article" @default.
• W4385655505 hasAuthorship W4385655505A5016162569 @default.
• W4385655505 hasAuthorship W4385655505A5016725149 @default.
• W4385655505 hasAuthorship W4385655505A5029343418 @default.
• W4385655505 hasAuthorship W4385655505A5058079493 @default.
• W4385655505 hasAuthorship W4385655505A5067920206 @default.
• W4385655505 hasAuthorship W4385655505A5069294276 @default.
• W4385655505 hasAuthorship W4385655505A5075491391 @default.
• W4385655505 hasAuthorship W4385655505A5086673665 @default.
• W4385655505 hasBestOaLocation W43856555051 @default.
• W4385655505 hasConcept C121332964 @default.
• W4385655505 hasConcept C121608353 @default.
• W4385655505 hasConcept C126322002 @default.
• W4385655505 hasConcept C141071460 @default.
• W4385655505 hasConcept C142424586 @default.
• W4385655505 hasConcept C143998085 @default.
• W4385655505 hasConcept C197934379 @default.
• W4385655505 hasConcept C2776530083 @default.
• W4385655505 hasConcept C2776694085 @default.

• next